Clovis Oncology (CLVS) Stock Gains as Shareholders Reject Reverse Stock SplitInvestorPlace • 07/08/22
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual MeetingBusiness Wire • 06/14/22
Clovis Oncology's Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD StatusBusiness Wire • 06/06/22